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Objectives: Multi-criteria decision analysis (MCDA) has been recommended to support policy making in healthcare. However,
practical applications of MCDA are sparse. One potential use for MCDA is for the evaluation of programs for complex and
vulnerable patients. These complex patients benefit from integrated care programs that span healthcare and social care and
aim to improve more than just health outcomes. MCDA can evaluate programs that aim to improve broader outcomes
because it allows the evaluation of multiple outcomes alongside each other. In this study, we evaluate an innovative
integrated care program in the Netherlands using MCDA.
Methods: We used an innovative MCDA framework with broad outcomes of health, well-being, and cost to evaluate the Better
Together in Amsterdam North (BSiN) program using preferences of patients, partners, providers, payers, and policy makers in
the Netherlands. BSiN provides case management support for a period of 6 months. Seven outcomes that previous research has
deemed important to complex patients weremeasured, including physical functioning and social relationships and participation.
Results: We find that the program improved the overall MCDA score marginally, and, thus, after 6 and after 12 months, BSiN
was preferred to usual care by all stakeholders. BSiN was preferred to usual care, mostly owing to improvements in psy-
chological well-being and social relationships and participation.
Conclusions: The integrated healthcare and social care program BSiN in the Netherlands was preferred to usual care according
to an MCDA evaluation. MCDA seems a useful method to evaluate complex programs with benefits beyond health.
Keywords: complex care, discrete choice experiment, health technology assessment, multi-criteria decision analysis, well-
being.
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The care of vulnerable complex patients suffers from frag-
mentation and a lack of person centeredness.1-3 Complex patients
are those who not only experience multiple (physical and mental)
chronic conditions but also functional and cognitive impairments
and social and financial problems.2 These vulnerable patients need
complex care that is targeted to more than just improving health
and have significant nonmedical needs.2,4 Integrated care is pro-
posed as a solution and is aimed to achieve high-quality and cost-
effective care for complex patients.5,6 Integrated care is defined as
care that is coordinated, proactive, person centered, and provided
by 2 or more care professionals. As a response to the needs of
complex patients, innovative programs have been established.
One integrated care program for complex patients in the
Netherlands is the program “Better Together in Amsterdam North”
(Dutch acronym: BSiN). BSiN provides a period of intensive case
management. During the case management process, the case15 - see front matter Copyright ª 2021, ISPOR–The Professional Society for
cess article under the CC BY license (http://creativecommons.org/licenses/bmanager and the BSiN patient develop a targeted “life action plan,”
which they aim to execute over 6 months. This case management
approach ensures that all thevarious careproviders arewell aligned
and that the individual is seeking the right type of care from the
right services. The BSiN program is made up of an alliance of 12
healthcare and social care provider organizations, representing
primary healthcare (eg, general practitioners), secondary health-
care (hospital), mental health services, welfare (debt services case
managers and social workers), and social security (municipality
return-to-work coordinators, home-care services). Thus, what is
particularly unique about BSiN is the emphasis on problems in
multiple domains such as health, financial, or housing problems.
The evidence of the effectiveness and cost-effectiveness on
integrated care for vulnerable people with complex needs is
sparse and mixed7 making implementation, upscaling, or contin-
uation of these programs difficult. Evaluating integrated care
programs, such as BSiN, is challenging because these are complex
multi-faceted interventions8 that aim to improve the “Triple Aim”:Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
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costs.8 Owing to this complexity, traditional cost-effectiveness
evaluations that focus on health outcomes and costs are not suf-
ficient for the evaluation of integrated care programs.8 A broad
evaluation method needs to be applied that investigates multiple
outcomes.9 In addition, these programs require a joint effort by
various stakeholders, such as patients, informal care takers, pro-
fessionals, payers, and policy makers, and, thus, all their views
should be considered.9
Multi-criteria decision analysis (MCDA) can provide a decision-
making technique for evaluating integrated care because it can
include multiple outcomes10 that cover the Triple Aim. In MCDA,
the “criteria” (or outcomes) can be reviewed separately but also
integrated into 1 score by applying a weighting to the outcomes.10
In addition, MCDA can consider multiple perspectives by using
different weights, reflecting the different preferences of the
different stakeholders.10 The MCDA process facilitates decision-
making about integrated care programs by providing a struc-
tured and explicit process to evaluate BSiN. Although MCDA has
been recommended as a means to support decision-making, its
use remains limited.11 Indeed, there remain questions about the
implementation of MCDA particularly around the selection of the
right outcomes, methods of weight elicitation, methods for un-
certainty analysis, and whether costs should be an outcome.11
Thus, there remains a gap in the literature for the methodolog-
ical implementation of MCDA for evaluation programs in health-
care and social care. This article attempts to present a solution to
these methodological problems.
A recent European Horizon 2020–funded project has devel-
oped a novel MCDA framework, that is, a particular application of
MCDA, with the aim to be applicable to evaluate a wide variety of
integrated care programs.9 This study aimed to implement MCDA
to assess the value of the BSiN approach as opposed to usual care
for those with complex multiple problems and thereby also to
contribute to the methodology and use of MCDA in healthcare
decision-making.Methods
Intervention
BSiN implemented a case management intervention in
Amsterdam North, in the Netherlands. The population of
Amsterdam North has on average a lower socioeconomic status
and relatively high healthcare and social care costs than the rest of
the city.2 BSiN assigns a case manager to each individual. Case
managers receive special training and develop individualized care
plans together with the individuals enrolled in the program. A
typical case management trajectory takes 6 months. After 6
months, the case management could be extended but in practice
was provided only for 6 months.
Target Population
Individuals with a potential to be eligible for enrolment in BSiN
were identified and referred to a multidisciplinary triage team
that includes a general practitioner, a psychiatrist or psychiatric
nurse, a district nurse, and a social worker. Only those aged more
than 18 years were eligible for the intervention. Individuals
entering BSiN were screened using the Self-Sufficiency Matrix
(SSM)12, which assesses an individual’s self-sufficiency in 11 life
domains: finances, daily activities, housing, relationships at home,
mental health, physical health, addiction, activities of daily living,
the social network, social participation, and justice.12 Individualswith limited self-sufficiency or lower on at least 3 of the 11 life
domains were assigned to case management.
The control group could not be based on randomization of the
intervention population because of ethical reasons. Instead, a
control group was recruited among residents aged between 18
and 65 years in Amsterdamwho filled out the “Amsterdam Health
Monitor Survey” in 2012 or 2016.13 In the survey of 2012 and 2016,
individuals with negative outcomes on the social exclusion index
or on the psychological distress scale14,15 were identified as
potentially eligible control group participants. All eligible potential
control group participants were requested to take part in a face-
to-face interview where the actual SSM was determined by a
trained interviewer. If the individual scored limited self-
sufficiency on at least 3 of the 11 SSM domains, they were
included in the control group and the first measurement for the
control group participant was undertaken. Using this method, it
was possible to form a control group while complying with
medical ethics. Because the control group could not be random-
ized, statistical techniques were applied to ensure that the inter-
vention and control were more similar on observable
characteristics (see the Statistical Analysis section).
MCDA Framework and Decision Context
The MCDA framework was developed around established
guidelines and follows the 7 recommended steps (1) establish the
decision context, (2) identify and structure criteria, (3) determine
the performance on criteria, (4) determine the weights of the
criteria, (5) create an overall value score, (6) perform sensitivity
analyses, and (7) interpret results.10,16 In the first step, the aim is to
establish what the likely decisions are that need to be made and
thus how theMCDAwill be used.10,16 Earlier analysis of the decision
context of BSiN revealed that the program context is to provide
evidence on the effectiveness of the program, to help establish the
long-term sustainability, and potentially widen implementation of
the program in the region.17,18 Hence, the aim of the MCDA was to
inform these decisions by comparing the programwith usual care.
In addition, it is important to identify the relevant stakeholders in
this decision-making process. The stakeholders that were consid-
ered relevant were 5 groups: patients, partners and other informal
caregivers, professionals, payers, and policy makers.17,18
Outcomes and Preferences
In the Sustainable Integrated Care Models for Multimorbidity:
Delivery, Financing, and Performance (SELFIE) project, we
selected a set of 8 outcomes that measure the Triple Aim10:
improving population health and well-being, improving experi-
ence with care, and reducing costs (growth). These 8 outcomes
are chosen to be applicable to a wide range of interventions for
complex patients. This selection was based on a literature review,
workshops with representatives from the 5 stakeholder groups,
and focus groups with individuals with multimorbidity.17 To
measure health and well-being, we included outcomes on
physical functioning, psychological well-being, social relation-
ships and participation, enjoyment of life, and resilience. To
measure experience of care, we included outcomes on person
centeredness and continuity of care. Finally, to measure costs we
included program intervention costs and total healthcare cost of
each individual. The inclusion of cost as an outcome implies that
the opportunity costs of resources are determined by those
providing the preferences weights16,18 and not by a (nationally)
determined threshold similar to a quality-adjusted life year
threshold. This can be justified because the decision context of
BSiN and many other integrated care programs is whether to
continue or roll out programs. The decision maker in this context
Table 1. Outcomes measured in MCDA.
Criteria Item Scale
Physical functioning 10 ADL questions of the “Groningen Activity
Restriction Scale”:
Eating and drinking
Sitting and standing up from a chair
Getting in and out of bed
Getting dressed and undressed
Moving within the house
Moving up and down stairs
Entering and existing the house
Moving outside the house
Washing and face and hands
Washing yourself completely
Each item has 4 response options:
1 = only with help of others
2 = with great effort
3 = with some effort
4 = without effort
Psychological well-being Over the past year, did you ever feel gloomy or
sad?




4 = once in a while
5 = never
Social relations and participation Do you ever feel alone or lonely? The item has 3 response options:
1 = yes
2 = more or less
3 = no
Resilience If something bad happens, can you handle it
well?
The item has 3 response options:
3 = able to deal with setbacks
2 = neutral
1 = not able to deal with setbacks
Person centeredness Three items relating to planning with a case
manager:
1. Is the plan available?
2. Is the plan read?
3. Is the plan understood?
Each item has 2 response options:
1 = yes
0 = no
Continuity of care Do you have 1 care provider whom you can
approach with all your problems?
The item has 2 response options:
1 = yes
0 = no
Total costs Total cost (including primary care, secondary
care, and medication) as part of the basic Dutch
insurance package
Outcome measured in V between V250 a month
and V2083 a month
ADL indicates activity of daily living; MCDA, multi-criteria decision analysis.
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sufficient benefits over an alternative program to continue
investing in it rather than whether investment should be made.
One benefit of including cost as an outcome is that the additional
investment is directly compared with the additional non-cost
outcomes, thus incorporating the justification of any in-
vestments. Furthermore, because reduction in costs (growth) is
one of the aims of integrated care programs, it should be
considered alongside other outcomes.
A questionnaire was developed by the Netherlands Organisa-
tion for Applied Scientific Research to collect data on the health/
well-being and care experience with measurements at baseline,
at 6 months, and at 12 months. This questionnaire consisted of a
range of existing patient reported validated items (eg, the Gro-
ningen Activity Restriction Scale19 and the Vita-1620) and was
administered by trained interviewers at the participants’ home.
Interviews lasted 45 to 60 minutes. All items were piloted before
being used in interviews and adapted where needed. A list of
outcomes is presented in Table 1.
Cost data were obtained from claims data from a Dutch health
insurance firm “Achmea Zilveren Kruis.” The company claims
database of the Achmea was linked using personal data to data
from individuals in the study through a trusted third party(to protect the identity of participants). The claims data contain
healthcare cost data from the basic Dutch health insurance. Data
on expenditure from individuals on medicine, mental health,
primary care, and secondary care are included in this dataset.
These claims data do not include social care services because they
are not paid for by the insurance company. In addition, cost data
from the organizations providing case management were avail-
able in the reports of the BSiN alliance of healthcare and social
care provider organizations.
For each outcome, the relative importance of each outcome for
each stakeholder group was measured using a discrete choice
experiment (for full details of how these preference weight were
obtained, see9,21) with the 5 relevant stakeholder groups in the
Netherlands. In the discrete choice experiment, individuals
belonging to these stakeholder groups were asked to make
choices among programs with different performances on each
outcome. Each program was described in terms of 8 outcomes
where each outcome had 3 levels of performance. Thus, re-
spondents selected which program they thought would be better
for someone with multimorbidity and thereby revealed what
outcome was most important to them. Patients, partners, and
providers were primarily recruited from an online panel whereas
payers and policy makers were recruited using networks of the
HEALTH POLICY ANALYSIS 969study authors and a snowball sampling method. By analyzing their
choices using a multinomial logit model, the relative importance
of each outcome was obtained.9,21 Thus, these preference weights
reflect the difference in preference between a good performance
and poor performance on each outcome.
Statistical Analysis of Performance Score Calculation
In MCDA, for each different outcome that was measured (eg,
physical), the performance score (PS) (ie, how patients rate their
physical functioning) must be estimated to assess how well each
program performed. The performance of BSiN compared with
usual care at 6 months and 12 months was estimated. Because
there was no randomization and the control and intervention
groups were recruited in different ways, the participants in the 2
groups were likely to differ in relevant characteristics. To increase
comparability of characteristics in the 2 groups and reduce con-
founding, we performed inverse probability weighting.22,23
Inverse probability weighting was used in an attempt to
rebalance the composition of the control group to match that of
the intervention group by weighting those in the control group
most similar to the intervention group more heavily.22,23 To
calculate the inverse probability weighting, we included the
following variables: gender, age, education, living situation,
marital status, financial problems, work status, volunteer work,
housing problems, number of chronic diseases, number of SSM
domains on which the score is less than 3, and self-perceived
health. This results in a weight that reflects the estimated prob-
ability that someone would be in the intervention group. We es-
timate the average treatment effect on the treated by setting the
weights for each individual in the intervention group to 1 and for
each individual in the control group to p/(1-p), with p being the
estimated probability that an individual is in the intervention
group. To assess whether the inverse probability weighting
improved the comparability of the intervention and control group,
a set of matching statistics were used. Three matching statistics
were calculated: Rubin’s B (the standardized difference of the
means of the linear index of the propensity score in the treated
and non-treated group), Rubin’s R (the ratio of treated to non-
treated variances of the linear index of the propensity score),
and the median absolute standardized bias (which is the median
of the ratios of the difference of the sample means in the treated
and non-treated groups over the square root of the average of the
variances in both groups).24
To analyze the performance on outcomes, we used repeated
measurement models with individual-level random effects, to
account for the fact that individuals were followed up over time,
and we used an intention to treat analysis. We use models
assuming continuous outcomes for ease of interpretation, only for
continuity of care did we use a binary logit regression to constrain
the predicted values to a 0 to 1 range. The following regression
was estimated for each outcome separately:
Yjt ¼ b01b1Cn1dt  Tt1gt  Tt  Cn1uj1ejt
where Yjt is the outcome for person j at time t, is the random
intercept variance term, Cn indicates whether the observation is
from the intervention or control cohort, and Tt indicates whether
the observation is from time point 0, 6, or 12 months. b and d are
a set of regression coefficients. The treatment effects are given by
the regression coefficients gt. It should be noted that all out-
comes were included in the MCDA regardless of statistical sig-
nificance, because a treatment effect that is not statistically
significant is not zero,25 and because later described MCDAuncertainty analysis takes the uncertainty in treatments effects
into consideration.
To calculate PSs, we predict the mean score of the intervention
group at 6 months and at 12 months based on the regressions
results. In addition, we calculate the mean score of the control
group assuming they had the same baseline as the intervention
group. In this way, the calculated PSs can be directly compared
between the intervention and control group. This is done sepa-
rately for each outcome.
Performance scorent ¼b01b1  Cn¼11dt  Tt1gt  Tt  Cn
To incorporate the performance scores with weights, we first
normalize the PSs to a range of 0 to 1. This removes the difference
in scales among all PSs. Normalization is done by:
Normalized performance scores ¼
performance scoreseminimum score
maximum scoreeminimum score
We take the range of each outcome as the minimum and
maximum. For costs, we took a range based on the existing costs
of care for this group of patients and program cost from the
literature (V250–V2083 a month). We then multiplied the
outcome weight of stakeholder group with the normalized per-
formance to obtain the partial value, and we sum the partial value
to obtain the overall scores.
Overall Value Calculation
Finally, to combine preference weights and PSs of each
outcome into an overall value score considering all outcomes, we




Probabilistic sensitivity analysis (PSA) using Monte-Carlo simula-
tion was conducted to assess the joint uncertainty of preference
weights and PSs. We use the Cholesky decomposition to draw
correlated draws26 from the distributions of both performance
estimates and the weights for 10 000 repetitions. The overall
scores are then combined as previously described. From this, we
ascertain how often the integrated care program has an overall
score better than the usual care, and we obtain the confidence
interval (CI) of the overall scores based on the 95% percentile
method. All analysis was conducted in Stata 15 (StataCorp.
2017. Stata Statistical Software: Release 15. StataCorp LLC, College
Station, TX).Results
Sample Characteristics
The background characteristics of the sample are presented in
Table 2. Before inverse probability weighting, there are differences
between the groups. The intervention group scores low on SSM
with over 6 domains being declared insufficient, indicating that on
a wide range of life domains they are not self-sufficient. In general,
the control group has better baseline outcomes, for example, the
control group scores better on the SSM with less domains in crisis
and has less financial problems. After inverse probability
weighting, many of these differences are reduced and indeed the
matching statistics of Rubin’s B and median absolute standardized
Table 2. Descriptive statistics of baseline background characteristics and outcomes.
Variables Before matching After matching
Intervention Control Control
Data used for the non-cost outcomes
Subject characteristics
Sample size 74 161
Men, % 35 41 39
Age, mean 53 (13) 58 (11) 58 (9)
High education level, % 31 54 47
Living together, % 59 60 45
Financial problems, % 64 20 65
Paid employment, pension, of student, % 20 46 39
Volunteer work, % 18 29 24
Housing problems, % 9 1 3
Number of chronic diseases 3.5 (2.3) 3.3 (2.3) 4.5 (2.4)
Perceived health 3.6 (0.8) 3.1 (0.8) 3.7 (0.8)
Total SSM score, mean 3.3 (0.4) 4.2 (0.5) 3.6 (0.5)
Number of SSM domains that are vulnerable or in crisis, mean 6.3 (1.8) 2.5 (2) 5.5 (2.3)
Outcomes
Baseline outcome on physical functioning scale (SD) 2.4 (1.1) 2.7 (1.3) 2.1 (1)
Baseline outcome on psychological well-being (SD) 2.7 (1.2) 3.5 (1.1) 2.5 (1.1)
Baseline outcome on social relations and participation (SD) 1.9 (0.9) 2.4 (0.8) 1.8 (0.9)
Baseline outcome on resilience (SD) 2.3 (0.8) 2.5 (0.7) 1.9 (0.9)
Baseline outcome on continuity of care (SD) 0.9 (0.3) 0.2 (0.4) 0.4 (0.5)
Baseline outcome on person centeredness (SD) 0.8 (1.3) 0.5 (1.1) 0.1 (0.5)
Matching statistics
Rubin’s B 228 104
Rubin’s R 1.1 2.4
Median absolute standardized bias 46.5 32.1
Data used for the cost outcome
Subject characteristics
N at baseline 46 111
Men, % 0.39 0.41 0.40
Age, mean 55 (13) 61 (11) 55 (13)
Outcomes
Baseline total cost in first month V432.44 V679.88 V410.09
Matching statistics
Rubin’s B 52 5
Rubin’s R 0.9 0.68
Median absolute standardized bias 20.9 2.4
SD indicates standard deviation; SSM, Self-Sufficiency Matrix.
970 VALUE IN HEALTH JULY 2021bias show this for both the cost and non-cost outcomes. However,
Rubin’s R values are now further away from the ideal value of 1.
Treatment Effects
The treatment effects are presented in Table 3. At the mea-
surement after 6 months of intervention, we find a significant
effect for psychological well-being and the costs outcomes, with
BSiN performing better than usual care for psychological well-being but worse for costs. The improvement on psychological
well-being indicates that in the first 6-month period, those in BSiN
improved a full step on the 5 point scale and felt less “gloomy or
sad.” On costs the treatment effect is V1368, indicating that BSiN
is more costly than usual care. For other outcomes, there are 3
positive treatment effects and 2 negative treatment effects. The
treatment effects of physical functioning, social participation, and
continuity of care are positive, indicating BSiN has led to an










































































































Observations 427 422 420 416 226 427 471
Sample size 233 233 234 232 133 235 157
CI indicates confidence interval; Est, beta coefficient.
HEALTH POLICY ANALYSIS 971improvement on these 3 outcomes. On resilience and person
centeredness, there is a negative treatment effect, indicating BSiN
has led to a deterioration on these 2 outcomes.
At the third measurement point after 12 months (6 months of
intervention and 6 months of follow-up), we only obtained sig-
nificant negative (worse) results for resilience. For the other 6
outcomes no statistically significant effects were found, with 5 of
the treatment effects being positive whereas 1 was negative.
Similar to the second measurement, physical functioning, psy-
chological well-being, and social participation showed positive
treatment effects. Cost and person centeredness had positive
although essentially zero treatment effects, opposite to their
6-month treatment effects. At the second measurements,
continuity of care had a negative treatment effect, in opposite to
the 6-month measurement.MCDA Overall Scores
The weights for the SELFIE outcomes elicited from the 5 Dutch
stakeholder groups are reported in Figure 1 and in the Appendix I
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.02.007. The predicted scores for the MCDA, their standardized
scores, and the weighted scores that are presented in Table 4 (after
6 months) and 5 (after 12 months). After 6 months, BSiN was
preferred to usual care in the weighted score for all 5 stakeholders,
and this is mostly influenced by psychological well-being and
social relationships and participation. In particular at 6 months, it
is patients who prefer BSiN over usual care the most and policy
makers the least (Table 4).
After 12 months, BSiN is still preferred to usual care, which is
again mostly driven by psychological well-being. For patients,
the difference in total scores between BsiN and usual care is
reduced compared with the difference after 6 months. Thus,
patients had a stronger preference for BSiN than usual care at 6
months than at 12 months. For providers, payers, and policy
makers, the reverse is true, and their preference for BSiN
compared with usual care is improved at 12 months compared
with at 6 months (Table 5).Sensitivity Analysis
The PSA provides the 95% CI for the total value score. There is
in all cases an overlap between the CI of the intervention and
control. The PSA reveals that the intervention is preferred both
after 6 month and after 12 months in at least 55% of the runs. After
6 months for patients in 84% of the MCDA iterations, the inte-
grated care program has a higher overall value score than usual
care for patients. This is at the minimum of 55% for policy makers.
After 12 months, payers prefer BSiN the most (with 82% of cases)
and partners the least (with 65%).
Discussion
This study found that BSiN, an integrated care case manage-
ment program of 6 months for individuals with complex multiple
problems, showed an overall improvement, although the
improvement was not large. Most of the improvement was driven
by the psychological well-being and some by social relationships
and participation. BSiN performed the worst on costs, where there
were high costs of the intervention and this had not led to short
term savings that could offset those costs. Although all stake-
holders preferred BSiN to usual care, it was patients who preferred
it the most and policy makers the least. In the 6-month follow-up
period, where there was no case management provided, some of
the benefit was reduced, but this was also offset by improvements
in costs. Overall, BSiN was still preferred by all stakeholders to
usual care, which means that according to stakeholders the BSiN
program should continue to be implemented.
It is difficult to directly compare the results of BSiN with other
programs. Integrated care programs are highly complex in-
terventions, and comparing them with each other presents diffi-
culties owing to population and intervention heterogeneity.27,28 In
addition, there is little standardization of outcomes for these sort
of evaluations, and indeed many studies may not even focus or
include quality of life outcomes, although many do include care
utilization or costs.27 Overall previous research has shown that
case management delivers mixed results.29,30 Indeed, it could be
argued that also in BSiN the results are somewhat mixed, because
Figure 1. Relative preferences of different stakeholders across different outcome.
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HEALTH POLICY ANALYSIS 973although some outcomes were improved, this improvement was
not maintained when the 6-month trajectory of case management
was stopped. This indicates that the intervention period might
have been too short.
This study of BSiN also served as a case study to display the
potential of MCDA. Although theoretical discussion about MCDA
has been conducted,10,11,16,31 the number of real-life applications
remains limited.11 The SELFIE MCDA framework9 should be useful
for healthcare decision makers for the evaluation of complex
programs.32 The availability of the SELFIE MCDA framework can
provide a useful framework for designing the evaluation of these
programs. Particularly, MCDA provides 3 key benefits. First, it
provides a structured and explicit approach for evaluation of
complex programs. For example, in this case study, it was
apparent that on certain outcomes BSiN performed better than
usual care and in some it did not. MCDA allows decision makers to
use an explicit decision-making technique to aggregate the
various outcomes and to determine an overall score while
considering the preferences of stakeholders. If only the individual
treatment effects were available, an overall decision could not
have been made transparently. This MCDA evaluation process can
be applied to different integrated care interventions and thus can
ensure some consistency in valuation. It remains the case that
although there are many innovative integrated care initiatives
ongoing, program evaluation is often not included. Second, MCDAalso provides insight into disaggregated effectiveness on a set of
outcomes beneficial to a complex interventions. It can disentangle
the overall improvement by outcome and allows the use of a
broad range of outcomes, which is particularly important for
complex interventions that target complex patients with prob-
lems in multiple life domains. Indeed, it is even more important in
programs where one may expect improvements in 1 set of out-
comes but deteriorations in others, as was the case for BSiN. Many
existing evaluations tend to focus on health only and lack critical
aspects important for complex interventions. This was apparent in
the current evaluation of BSiN where one of the outcomes of the
core set of outcomes in the SELFIE project, namely, enjoyment of
life, was not measured as an outcome. Third, this MCDA frame-
work allowed the evaluation of BSiN using appropriate and
comprehensive outcomes on the Triple Aim. In a quality-adjusted
life year-based approach, for example, only the direct health
benefits and the costs would be included, and aspects such as
social relations and participation where BSiN differed from usual
care could not easily be included.
The literature has discussed the potential of MCDA but many
methodological issues are still outstanding,11,33 ranging from
which outcomes to include to how to assess uncertainty. The
SELFIE MCDA framework has systemically worked through several
of these issues. First, we made sure that deterioration in one
outcome could be compensated by improvement in other
974 VALUE IN HEALTH JULY 2021outcomes, and lack of overlap between outcome measures was
avoided to avoid double counting. Second, the PSs were deter-
mined using an evaluation with real patient data and not expert
elicitation. Lack of data sources need not be a problem because
existing questionnaires that have been validated for relevant
populations can be used to measure the recommended outcomes.
Third, a discrete choice experiment was used for weights because
of the strong theoretical basis involving trade-offs between out-
comes34 and because it takes account of the entire range of per-
formance11 of integrated care programs. Other weight elicitation
methods often do not take into account the full range of perfor-
mance possible and thus are criticized for their lack of validity.11
Fourth, uncertainty was formally incorporated using PSA Monte-
Carlo simulations on both weights and scores. Finally, the impor-
tance of including all stakeholders has been noted,31 which was
addressed by having weights from 5 important stakeholder
groups.
This study has some limitations. Owing to the nature of the
study population, a randomized trial was not possible. We have
attempted to reduce confounding and selection bias by intro-
ducing propensity score matching although even this is limited by
the small control group. Within the sample, we saw quite some
dropout, which was analyzed using intention to treat method,
which assumes the observations are missing at random.35 The
nature of a study with a vulnerable complex population makes it
unlikely that a study could be conducted with little dropout or a
very comparable control group. The results should be interpreted
considering these limitations, but it is difficult to speculate
whether the results would be biased in a particular direction
because of these limitations.
Future research should focus on developing stronger links
between outcomes and weights in the MCDA. In this study, we
have assumed that the performance scales and weight scales are
linearly related. It could be the case that the relation is not
linear. To investigate this may involve, for example, mapping
between the discrete choice experiment levels and the perfor-
mance scale. However, changing our assumption of linearity is
unlikely to affect the current results because the PSs of the
intervention and control group do not differ very much. Further
work could explore the role of cost if the decision context
changes. The current local context was to inform potentially
wider implementation of the program in the region. However,
for a more traditional health technology assessment approach to
inform allocation of resources on national level, costs could be
removed but a threshold for the maximum costs per unit gained
in the overall value score would have to be elicited or estimated.
Finally, further work could be obtained on the actual use of the
MCDA tool by decision makers to elucidate how stakeholders
want to engage with MCDA and precisely when and how it
contributes the most.33 Although the SELFIE MCDA framework
had a clear decision context attached, it may be used in others,
and potentially qualitative work with decision makers would
enable the literature to understand the best application of MCDA
in practice.
This study applied an MCDA to the evaluation of an innovative
health and social care program aimed at achieving self-sufficiency
with a group of people with multiple problems in the Netherlands.
The BSiN program showed an overall increase in value, but this
was mostly driven by a couple outcomes and the improvement
was reduced during follow-up. This case study shows that the
MCDA framework can be used to evaluate complex healthcare
programs and the strength of using multiple outcomes, valid
weights, and uncertainty analysis. Therefore, the SELFIE MCDA
framework should be able to achieve greater transparency and
better decisions in healthcare decision-making.Supplemental Materials
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